Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BME Conditioning for NHL Autologous Transplantation
NCT03792815Phase 2Completed
- Sponsor
- Soonchunhyang University Hospital
- Start
- Oct 2009
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan, melphalan and etoposide in Non-Hodgkin lymphoma (NHL), sponsored by Soonchunhyang University Hospital. Primary endpoint: Event Free Survival at 2 years. Started Oct 2009; status: completed.
02
Drugs
busulfanmelphalanetoposide
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03792815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03792815.